MFJ Stock Chart & Stats
€0.57
€0.01(0.84%)
At close: 4:00 PM EST
€0.57
€0.01(0.84%)
Day’s Range― - ―
52-Week Range€0.50 - €0.94
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€402.07M
Enterprise Value€847.73
Total Cash (Recent Filing)€29.26M
Total Debt (Recent Filing)€31.74M
Price to Earnings (P/E)59.8
Beta1.21
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding690,843,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.78Price Target Upside37.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Exceptionally High Gross MarginsSustained gross margins near 96% reflect strong product economics for NovoSorb consumables and a low variable cost base. High gross margins support reinvestment in commercial expansion, absorb one-off costs, and provide durable operating leverage as sales scale across markets over the next several quarters.
Strong Revenue Growth And U.S. Commercial TractionDouble‑digit group and U.S. growth with rapid account additions and a >80‑rep U.S. sales team indicate durable demand and scaled commercial capability. Broadening account base and diversified regional gains reduce concentration risk and support sustainable revenue growth over the medium term.
Significant Manufacturing Scale-up (~5x Capacity)A validated facility with roughly fivefold capacity expansion materially reduces supply constraints and enables multi‑SKU production and outpatient sizing. Increased capacity supports durable volume growth, lower unit bottlenecks, and margin recovery once throughput normalizes over coming quarters.
Bears Say
Weak Cash Generation MetricsNegative FCF growth and low operating cash conversion versus reported earnings indicate the company currently struggles to turn profit into free cash. This constrains funding for rollouts, RCTs, and working capital, raising reliance on financing or mindful capex phasing in the medium term.
Outpatient Reimbursement Uncertainty (CMS)Potential need for a dedicated RCT to secure CMS outpatient coverage creates meaningful timing and access risk. Outpatient is a structural upside, but reimbursement uncertainty means a sizable addressable market remains untapped until trial outcomes and coding decisions materialize, delaying durable revenue.
Lumpy Burn Market And SeasonalityCore burn case volumes are inherently variable and seasonal, creating persistent quarter‑to‑quarter revenue volatility. This lumpy demand complicates capacity utilization, inventory planning and near‑term forecasting, limiting visibility for multi‑quarter financial planning despite long‑term demand.
Polynovo News
MFJ FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest stock price was €0.50 and its highest was €0.94 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is €402.07M.
When is Polynovo Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Polynovo Limited’s earnings last quarter?
Currently, no data Available
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in DE:MFJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€0.78 (37.57% Upside)
€0.78 (37.57% Upside)
Blogger Sentiment
Bullish
DE:MFJ Sentiment 96%
Sector Average 65%
Sector Average 65%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Polynovo Limited
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
MFJ Stock 12 Month Forecast
Average Price Target
€0.78
▲(37.57% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―